1Gassier N, Eliger M, Krnzliin B, et al. Podocyte injury underlines the progression of focal segmental glomerulaoslerosis in the fa/fa Zueker rat. Kidney Int 2001 ;60(1) : 106-116.
2VestraMD, Masiero A, Roiter AM, et al. Is podocyte injury relevant in Diabetic Nephropathy? : Studies in patients with type 2 Diabetes. Diabete 2003; (52) : 1031 - 1035.
3Pavenstdt H, Kriz W, Kretzler M, et al. Cell biology of the glomerular podocyte. Physiol Rev 2003 ; 83, ( 1 ) : 253 - 307.
4Doublier S, Salvidio G, Lupia E, et al. Nephrin Expression Is Reduced in Human Diabetic Nephropathy Evidence for a Distinct Role for GlycatedAlbumin andAngiotensin Ⅱ . Diabetes 2003 ; (52) : 1023- 1030.
5Langham RG, Kelly DJ, Cox AJ, et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002 ; 45 ( 11 ) : 1572 - 6.
6Kim JM, Wu H, Green G, et al. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 2003 ; (300) : 1298 - 1300.
7Huber TB, Hartleben B, Kim J, et al. Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKr-dependent signaling. Mol Cell 8ioi 2003 ; (23) : 4917 - 4928.
8Topham PS, Kawachi H, Haydar SA, et al. Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin. J Clin Invest 1999; (104) : 1559 - 1566.
9Guo JK, Menke AL, Gubler MC, et al, WTI is a key regulator of podocyte function: reduced expression levels cause 'crescentic glomerulonephritis and mesangial sclerosis. Human Molecular Genetics 2002;(11):651-659.
10Kim YH, Goyal M, Wharram B, et al. GLEPP1 receptor tyrosine phosphatase(Ptpro)in rat PAN nephrosis. A marker of acute podocyte injury. Nephron 2002 ;90(4) :471 - 6.
2Li JJ, Kwak SJ, Jung DS, et al. Podocyte biology in diabetic nephropathy [J]. Kidney Int Suppl, 2007, (106): S36-S42.
3Dalla-Vestra M, Masiero A, Roiter AM, et al. Is podoeyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes [J]. Diabetes, 2003, 52(4):1031-1035.
4Barisoni L, Mundel P. Podoeyte biology and the emerging understanding of podoeyte diseases [J]. Am J Nephrol, 2003, 23(5) : 353-360.
5Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy [J]. Nephron Physiol, 2007, 106(2):p26-p31.
6Marshall SM. The podoeyte: a potential therapeutic target in diabeticnephropathy [J]? Curr Pharm Des, 2007, 13(26):2713- 2720.
7Shankland SJ. The podocyte's response to injury: role in proteinuria and glomeruloselerosis [J]. Kidney Int, 2006, 69 (12):2131-2147.
8Tryggvason K, Wartiovaara J. How does the kidney filter plasma [J]? Physiology (Bethesda), 2005, 20: 96-101.
9Zou J, Yaoita E, Watanabe Y, Yoshida Yet al. Upregulation of nestin, vimentin, and desmin in rat podocytes in response to injury [J]. Virchows Arch, 2006, 448(4): 485-492.
10Mundel P, Shankland SJ. Podocyte biology and response to injury [J]. J Am Soc Nephrol, 2002, 13(12): 3005-3015.
